The COVID-19 pandemic presented an excellent opportunity for CDMOs to showcase their reliability and expertise throughout the biopharmaceutical industry.
As COVID-19 vaccines and treatments are in production worldwide, pharmaceutical companies are demanding more and more from CDMO facilities — not only for COVID-related products, but for non-COVID injectables, tablets, and biotherapies. PWC estimates that the CDMO market will be worth $158 billion by 2025, increasing from $99 billion in 2018.
Related: How to Stay Ahead of the mRNA and Viral Vectors Process Validation Evolution
The Future of Contract Manufacturing
CDMOs are in a unique position to meet COVID-19 vaccine and treatment production needs for pharmaceutical companies but will need to advance in three critical areas according to a facility review from Pharma Manufacturing.
ICQ Prepares a CDMO for Vaccine Manufacturing Readiness
Long before the pandemic hit, a cell and gene therapy CDMO was working diligently to realize its dream of bringing life-saving therapies like viral vectors, vaccines, and oncolytic immunotherapies to patients.
But the facility was having trouble staying on track and was falling behind schedule and running over budget. Read how our team of experts got this facility back on track in time to support the COVID-19 response.
